Core Insights - The collaboration between Four环医药 and AbaloneBio aims to develop innovative obesity treatment drugs by targeting metabolic-related GPCRs to enhance energy expenditure while maintaining or increasing muscle mass [1][2] - The partnership is based on complementary strengths, with Abalone providing its core technology in GPCR antibody discovery and Four环医药 contributing its research and industrial resources in metabolic diseases [2] Group 1 - Four环医药 has signed a formal collaboration agreement with AbaloneBio to advance the research and development of next-generation obesity treatments [1] - The project focuses on overcoming the limitations of current weight loss therapies to meet unmet clinical needs in the global obesity treatment market [1] - GPCRs are a challenging target for drug development due to their complex structural requirements, and Abalone's unique functional antibody screening technology aims to address these challenges [1] Group 2 - The collaboration follows Four环医药's strategic investment in Abalone earlier this year, marking a transition from capital investment to business execution [2] - This partnership is expected to enhance Four环医药's innovative positioning in the weight loss sector and accelerate the development of new weight loss and muscle gain therapies [2] - The collaboration also represents a significant step in Four环医药's ongoing strategy to deepen its involvement in the GPCR target area, building on previous investments in related companies [2]
四环医药与美国AbaloneBio签署合作协议，联合开发新一代减重增肌创新疗法，进一步深化GPCR靶点领域布局